
CLAIMS

1. Use of a compound represented by the following structural formula:



Compound (I) , or a pharmaceutically acceptable salt thereof;

wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium;

wherein the compound, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hair loss disorder in a human subject, wherein the medicament is suitable for administration for (1) a first period of 8-24 weeks in an amount in the range of about 8 mg to about 32 mg per day, followed by (2) a second period of at least 8 weeks wherein the compound, or pharmaceutically acceptable salt thereof, and wherein the medicament is suitable for administration in an amount per day that is 50 to 75 percent of the amount per day suitable for administration during the first period.

2. The use of claim 1, wherein the hair loss disorder is alopecia areata.

3. The use of any one of claims 1-2, wherein, in the first period, the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration at about 16 mg/day, about 24 mg/day, or about 32 mg per day.

4. The use of any one of claims 1-3, wherein, in the second period, the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration at about 8 mg/day, about 12 mg/day, or about 16 mg per day.

5. The use of any one of claims 1-4, wherein in the first period, the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration at about 24

mg/day, and in the second period, the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration at about 16 mg/day.

6. The use of claim 5, wherein the about 24 mg/day of the compound or salt thereof is suitable for administration once per day, and the about 16 mg/day is suitable for administration once per day.

7. The use of claim 5, wherein the about 24 mg/day of the compound or salt thereof is suitable for administration as about 12 mg twice per day, and the about 16 mg/day of the compound or salt thereof is suitable for administration as about 8 mg twice per day.

8. The use of any one of claims 1-4, wherein in the first period, the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration at about 16 mg/day, and in the second period, the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration at about 8 mg/day.

9. The use of any one of claims 1-8, wherein the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration orally.

10. The use of any one of Claims 1-9, wherein the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration in a pharmaceutical formulation which is a tablet.

11. The use of any one of claims 1-6 or 8-10, wherein the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration once per day in the first period.

12. The use of any one of claims 1-5 or 7-10, wherein the compound, or a pharmaceutically acceptable salt thereof, is suitable for administration twice per day in the first period.

13. The use of any one of claims 1-12, wherein the first period is about 8-12 weeks.

14. The use of any one of claims 1-12, wherein the first period is about 24 weeks.

15. The use of any one of claims 1-14, wherein the second period is at least 12 weeks.

16. The use of any one of claims 1-15, wherein the second period is at least 24 weeks.

17. The use of any one of claims 1-16, wherein in Compound (I), each position designated specifically as deuterium has at least 97% incorporation of deuterium.

18. The use of any one of claims 1-17, wherein the subject experiences a ≥50% decrease in SALT score at the end of the first period relative to the subject's baseline SALT score prior to the use.

19. The use of any one of claims 1-18, wherein the subject's SALT score is less than or equal to 20 at the end of the second period.

20. The use of any one of claims 1-17, wherein the subject's SALT score is less than or equal to 20 at the end of the first period.